RxEars Rxi vs Signia Pure C&G IX

The RxEars Rxi is a budget-priced prescription hearing aid in an invisible-in-ear style, earning an A grade with a SoundScore of 4.1/5 in our lab testing. At $499, it represents one of the most affordable options in the prescription hearing aid category while still delivering solid overall performance. Speech clarity is a notable strength for this device. In quiet listening environments, the Rxi scores 4.3/5, which is 0.97 points above the category average—a strong result that should benefit users in conversational settings at home or in calm environments. Speech understanding in noisy conditions scores 2.1/5, slightly above the category average by 0.16 points, though this remains mixed in absolute terms and may present challenges in demanding acoustic situations like busy restaurants. Feedback handling is excellent at 4.7/5, essentially matching the category average and indicating reliable stability during daily wear. However, the Rxi shows notable limitations in other areas. Own-voice comfort scores 1.6/5, falling 1.15 points below the category average, which may result in a hollow or boomy perception of your own voice. Music streaming is not supported, scoring 0.0/5—a significant gap of 2.64 points below category average that buyers should consider if streaming audio matters to them. The RxEars Rxi is best suited for budget-conscious consumers who prioritize speech clarity in quieter environments and don't require streaming capabilities. Its invisible form factor and disposable battery design offer convenience, though those seeking better own-voice comfort or music features should explore alternatives.

The Signia Pure C&G IX is a premium prescription behind-the-ear hearing aid released in 2023, currently available at $3,298. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.1/5, ranking #20 among 36 prescription hearing aids tested. This device demonstrates consistent strength across multiple performance areas. Speech in quiet scored a solid 4.0/5, sitting 0.65 points above the category average. Speech in noise performance, while above the category average by 0.25 points, remains mixed in absolute terms at 2.2/5—a common challenge across prescription devices. Feedback handling is a standout feature, achieving a perfect 5.0/5 and exceeding the already-high category average. Own-voice comfort scores a solid 3.2/5, running 0.45 points above the category average, which suggests good occlusion management. Music streaming performs solidly at 3.0/5, also above average for the category by 0.36 points. The device supports both iPhone and Android streaming along with hands-free functionality. Professional tuning yields meaningful improvement, with the normalized score increasing from 4.0/5 to 4.5/5. Buyers seeking top-tier performance in this price range should note that competitors like the Phonak Sphere Infinio (5.0/5) and Oticon Intent (4.85/5) scored higher in our testing. The Pure C&G IX may suit those who prioritize reliable feedback control and balanced everyday performance over maximum speech-in-noise capability.